Table 3 DRPs and pharmacists’ interventions for home-isolating COVID-19 patients who received favipiravir as an antiviral treatment between July 2021 and September 2021
DRPs and pharmacists’ interventions | N (%) (Total N = 197) |
|---|---|
DRPs | 125 (63.45) |
Adverse reactions | 85 (68.00) |
Diarrhea | 32 (37.65) |
Dizziness | 15 (17.64) |
Constipation | 8 (9.41) |
Nausea | 7 (8.23) |
Gastrointestinal discomfort | 7 (8.23) |
Somnolence | 6 (7.06) |
Headache | 5 (5.88) |
Vomiting | 3 (3.53) |
Dry throat/mouth | 3 (3.53) |
Chest tightness | 2 (2.35) |
Blurred vision | 2 (2.35) |
Faint | 2 (2.35) |
Rash | 2 (2.35) |
Fatigue | 2 (2.35) |
Sweating | 1 (1.18) |
Palpitation | 1 (1.18) |
Insomnia | 1 (1.18) |
Hair loss | 1 (1.18) |
Joint pain | 1 (1.18) |
Back pain | 1 (1.18) |
Unnecessary use of products as part of the therapya | 78 (62.40) |
Nonadherence with medication for chronic illness | 8 (6.40) |
Needs for additional drug therapy | 3 (2.40) |
One patient had lung tuberculosis and needed additional therapy for the management of tuberculosis | |
One patient was complaining about psychological symptoms (e.g., insomnia and anxiety) | |
One patient had psoriasis and reported an exacerbation of the pathology’s skin-related symptomatology during home isolation | |
Number of recommendations to the COVID-19 patients | 36 |
Number of questions received from COVID-19 patients | 33 |